September 11th 2024
Your daily dose of the clinical news you may have missed.
September 10th 2024
September 6th 2024
Across two clinical trials in the QWINT program, once-wekly efsitora showed comparable A1C reduction to frequently used daily insulins.
September 3rd 2024
August 29th 2024
When Statin Guidelines Collide: 5 Questions on 2 Approaches to Primary CVD Prevention
Guidelines on primary ASCVD prevention from the USPSTF and the AHA/ACC/Multisociety differ on why and when to initiate a statin. Try the 5-question quiz.
Prescription Digital Behavioral Therapeutic for Type 2 Diabetes Wins FDA Marketing Clearance
AspyreRx™, prescribed in 90-day increments, resulted in a mean HbA1c reduction of 1.3% at 180 days in 1 out of 2 phase 3 trial participants. A Q4 launch is anticipated.
Daily Dose: T2D Raises Risk for Hepatic Decompensation, Hepatocellular Carcinoma in Patients with NAFLD
Your daily dose of clinical news you may have missed.
In Patients with NAFLD, Type 2 Diabetes Significantly Ups Risk for Hepatic Decompensation, Hepatocellular Carcinoma
In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .
Expert to Primary Care: Use these "ABCs" to Manage Obesity and T2D
The importance of avoiding judgement, monitoring behavior, and cardiovascular risk prevention in primary care are discussed, here.
Daily Dose: Loneliness and CVD Risk in Patients with Diabetes
Daily Dose: Childhood Glycemic Measures as Predictors of Diabetes-Related Complications
Treating Obesity & T2D: Experts Say Simultaneous, Early Intervention is Key
Early intervention is crucial to help prevent complications in patients with obesity and type 2 diabetes. Two experts explain more, here.
Loneliness Linked to Greater Risk for CVD in Individuals with Diabetes
The predictive value of loneliness for cardiovascular disease in patients with diabetes was stronger than traditional lifestyle risk factors in large UK Biobank analysis.
Glycemic Screening in Childhood May Predict Diabetes-Related Complications, According to New Data
ADA 2023: Findings from a new study show that higher levels of glycemia in childhood are associated with future microvascular complications, such as nephropathy and retinopathy.
Daily Dose: HF, CV Benefit of SGLT-2 Inhibition Consistent in T2D, CDK, HF
Health Inequities in Persons with Obesity & Type 2 Diabetes Exacerbated During COVID-19 Pandemic
Listen to 2 obesity experts discuss the impact of the COVID-19 pandemic on obesity-related type 2 diabetes.
New Data Suggest Higher Doses of Oral Semaglutide Beneficial for Management of Type 2 Diabetes
ADA 2023. Results from PIONEER PLUS trial showed oral semaglutide 25 mg and 50 mg were superior than 14 mg in reducing HbA1c and body weight in adults with T2D.
Daily Dose: Tirzepatide Leads to 15% Weight Loss in Adults with Obesity, T2D
SURMOUNT-2: Tirzepatide Treatment Leads to Average 15% Weight Loss in Adults with T2D, Obesity
ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.
Global Diabetes Prevalence Will Double by 2050, Affecting 1.3 Billion People: New Predictions
Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.
“Triagonist” Therapy for Type 2 Diabetes and Comorbidities to be Previewed at 2023 ADA Scientific Sessions
ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.
SGLT-2 Inhibitor HF, CV Benefit Found Consistent Across Populations with T2D, CKD, HF
SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.
Obesity & Type 2 Diabetes: Early Intervention Critical in Reducing Risk for Complications
Early intervention is important to reduce the risk for complications for patients with obesity and type 2 diabetes. Two obesity experts explain more, here.
Empagliflozin and Empagliflozin/Metformin Win FDA Approval for Pediatric Type 2 Diabetes
The 2 SGLT-2 inhibitor-based medications are the first in the class to be approved for pediatric T2D and provide a much needed additional oral treatment option for the population.
Early Time-restricted Feeding Regimen Improves Glycemic Variability, Time in Range in Patients with Prediabetes, Obesity
ENDO 2023. The pattern of intermittent fasting improved glycemic measures in a weight-independent fashion after just 7 days, according to the study abstract.
Daily Dose: Finerenone Reduces CKD-associated CV Risk in Patients with T2D
Finerenone Reduces CKD-associated Composite Cardiovascular Risk in a New Subanalysis of FIDELITY Trial
Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.
Daily Dose: Flash CGM Improves Glycemic Control in Patients with T2D Using Noninsulin Therapies
7 Questions on Managing Patients with Diabetes at High Risk of Hypoglycemia
Try this 7-question quiz on the 2023 guidelines from The Endocrine Society that focus on advances in diabetes treatment that help minimize risk of hypoglycemia.
CGM Uptake for T2D in Primary Care and Endocrinology: Rates, Correlates, Considerations
Prescriptions for continuous glucose monitoring for patients with T2D are increasing, a new study finds, and the authors report on characteristics of new CGM users.
Daily Dose: Adherence to GLP1RA, SGLT2i Therapies & Prescription Copayment Level
Endocrine Society Recommendations on How to Avoid Hypoglycemia in Patients with Diabetes: A Guideline Topline
The Endocrine Society's first update on management of hypoglycemia since 2009 emphasizes the value of new technology and therapeutics in minimizing risk.
Lower Adherence with GLP1RA, SGLT2i Therapies Linked to Higher Prescription Copayments
In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.
FDA Posts Warning on Compounded Semaglutide Products, Citing Reports of Adverse Events
Compounded versions of semaglutide, often sold online, may contain salt versions of the molecule and are not evaluated by the FDA for safety or efficacy.